Company Profile
Voyager Therapeutics Stock Price, News & Analysis
- Ticker:
- VYGR
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
3.13 USD (+0.97%)
Close
Last updated: August 6, 2026
217M USD
Market cap
Why the stock is moving
The latest monitored company update is “Voyager Reports Second Quarter 2026 Financial and Operating Results.” The corresponding closing-price reaction is not yet available.
Company overview
Neurologic Genetic Medicines
Voyager Therapeutics develops genetic medicines for neurologic diseases using human genetics and novel delivery technology. Its pipeline includes wholly owned and partnered programs.
TRACER Capsid Platform
The TRACER platform discovers adeno-associated-virus capsids designed to reach the central nervous system after intravenous dosing. These capsids support gene-replacement and gene-silencing programs.
Tau-Directed Alzheimer's Programs
VY1706 is a tau-silencing gene therapy approaching clinical development, while VY7523 is an anti-tau antibody already undergoing clinical evaluation in Alzheimer's disease.
Partnered Friedreich's Ataxia Program
NBIB-223 is a Neurocrine-partnered gene therapy for Friedreich's ataxia that has completed IND-enabling toxicology.
Future catalysts
IND application process for VY1706 in the second quarter of 2026.
First-in-human dosing of VY1706 in Alzheimer's disease in the second half of 2026.
Tau PET imaging efficacy data from the VY7523 study in the second half of 2026.
Initiation of a clinical trial of NBIB-223 in Friedreich's ataxia in the second half of 2026, pending IND clearance.
Recent news
- 01
Voyager Reports Second Quarter 2026 Financial and Operating Results
Source: Voyager Therapeutics
- 02
- 03
- 04
Voyager to Present at H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference
Source: Voyager Therapeutics
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Voyager Therapeutics (VYGR)?
Voyager Therapeutics (VYGR) most recently closed at 3.13 USD, a +0.97% move versus the previous session.
What is the market cap of Voyager Therapeutics (VYGR)?
Voyager Therapeutics currently has a market capitalization of 217M USD on BioPharmSignal.
What does Voyager Therapeutics do?
Neurologic Genetic Medicines Voyager Therapeutics develops genetic medicines for neurologic diseases using human genetics and novel delivery technology. Its pipeline includes wholly owned and partnered programs. TRACER Capsid Platform The TRACER platform discovers adeno-associated-virus capsids designed to reach the central nervous system after intravenous...
On which exchange is VYGR stock listed?
Voyager Therapeutics (VYGR) is associated with NASDAQ, United States, Biopharma.
What is NBIB-223?
Initiation of a clinical trial of NBIB-223 in Friedreich's ataxia in the second half of 2026, pending IND clearance.
Which conditions is Voyager Therapeutics targeting with NBIB-223?
Voyager Therapeutics is associated with genetic disease based on its company overview and current catalyst commentary.
How does Voyager Therapeutics describe recent progress with NBIB-223?
Initiation of a clinical trial of NBIB-223 in Friedreich's ataxia in the second half of 2026, pending IND clearance.
What is Neurologic?
Neurologic Genetic Medicines Voyager Therapeutics develops genetic medicines for neurologic diseases using human genetics and novel delivery technology.